Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.86 +0.62 (+2.56%)
Streaming Delayed Price Updated: 1:01 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election. 
Via Stocktwits
Topics Government Law Enforcement
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection. 
Via Stocktwits
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability. 
Via Benzinga
Tesla Senior Executive And Elon Musk Confidant Omead Afshar Leaves EV Giant Amid Dropping Sales, Days After Robotaxi Launch: Report
Afshar was promoted last year to oversee sales and manufacturing operations in North America and Europe. He previously worked in the office of the CEO. 
Via Stocktwits
Topics Artificial Intelligence
Pfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain Antibodies
During the study, 48 people living with hemophilia were treated with Hympavzi and observed to have a 93% reduction in annualized bleeding rate in 12 months. 
Via Stocktwits
Topics Death
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
From Pfizer Inc.
Via Business Wire
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts. 
Via Benzinga
Moderna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine Skeptics
RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots. 
Via Stocktwits
Pfizer Declares Third-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
3 Reasons PFE is Risky and 1 Stock to Buy Instead
Over the past six months, Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
10 Stocks That Pay $100 or More in Dividends
Via The Motley Fool
Topics Economy
2 S&P 500 Stocks on Our Watchlist and 1 to Think Twice About
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
The 5 Most Interesting Analyst Questions From Pfizer’s Q1 Earnings Call
Pfizer’s first quarter results drew a positive market response as management emphasized margin improvement and disciplined expense control, even as revenue declined. CEO Albert Bourla credited robust... 
Via StockStory
Topics Earnings World Trade
Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
With clinical catalysts on the horizon and a seasoned biotech insider doubling down, Could Nuvectis Pharma (NASDAQ:NVCT)* Become the Next Summit Therapeutics (NASDAQ: SMMT)? 
Via News Direct
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
1 Large-Cap Stock to Research Further and 2 to Turn Down
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
Curious about the most active S&P500 stocks in today's session?
Looking for the most active stocks in the S&P500 index on Wednesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market. 
Via Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
2 Top Stocks to Buy With Less Than $30
Via The Motley Fool
Topics Intellectual Property
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Looking for the most active stocks in the S&P500 index on Tuesday?
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest... 
Via Chartmill
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock
Via The Motley Fool
Topics Intellectual Property
3 Unprofitable Stocks with Mounting Challenges
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
1 S&P 500 Stock to Keep an Eye On and 2 to Steer Clear Of
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.